Fundraising Fox
/Companies
Sign in

Neuvasq

3 known investors

Find your way into Neuvasq

Each arrow is one introduction. Sign up to fill in the first one.

893 people can intro you to Denis

Ask Kate Antrobus to introduce you to Denis Bedoret

You →Kate · together at EXOTHERA →Denis

148 people can intro you to Benoit

Ask Jamie Chen to introduce you to Benoit Vanhollebeke

You →Jamie · together at Université libre de Bruxelles →Benoit

Sign up to find every way you can get introduced to Neuvasq

  • Your email: who you already know at Neuvasq, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Neuvasq team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Neuvasq Biotechnologies is a biotech spin-off from the Université libre de Bruxelles developing therapies that target the Gpr124/Reck signaling complex to repair the blood-brain and blood-CNS barriers in neurological and cerebrovascular disorders. The company translates research on brain vasculature and the blood-brain barrier into drug development programs.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

BVBenoit Vanhollebeke
Benoit VanhollebekeScientific FounderBenoit Vanhollebeke is a molecular biologist at Université libre de Bruxelles whose research focuses on neurovascular development and blood-brain barrier mechanisms; he founded Neuvasq Biotechnologies to translate this research into therapeutics targeting the blood-brain barrier for neurological disorders.
DBDenis Bedoret
Denis BedoretExecutive DirectorDenis Bedoret held CEO roles at a contract development and manufacturing organization focused on cell and gene therapy, and led operations at a contract research organization. He also worked in management consulting on strategy and operations, conducted medical research at academic institutions, and has experience across biopharmaceuticals, healthcare, chemicals, and other sectors.

Investors · 3

Sambrinvest✓ confirmed by NeuvasqCharleroi

How we know: the company's own site · Not right? Tell us

Wallonie Entreprendre✓ confirmed by NeuvasqLiège

How we know: the company's own site · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Newton Biocapital invests in Neuvasq: EUR 20 million Series A to develop unique blood-brain barrier therapy - Neuvasqneuvasq.com · Jun 2021

Frequently asked questions

What does Neuvasq do?
Neuvasq Biotechnologies is a biotech spin-off from the Université libre de Bruxelles developing therapies that target the Gpr124/Reck signaling complex to repair the blood-brain and blood-CNS barriers in neurological and cerebrovascular disorders. The company translates research on brain vasculature and the blood-brain barrier into drug development programs.
Who founded Neuvasq?
Neuvasq was founded by Benoit Vanhollebeke.
Who are Neuvasq's investors?
Neuvasq's investors include Newton Biocapital, Sambrinvest, Wallonie Entreprendre.